Table 2 Detailed description of patients with cardiovascular events
From: Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
Patient | Pre-/post-treatment LVEF | Clinical scenario | Attributable to Cfz? |
---|---|---|---|
1 | 65/45% | Multilobar pneumonia | Unlikely |
2 | 61/45%; 40% cycle 10 | Systemic sepsis | Unlikely |
3 | 63/35% | VTE/PE | No |
4 | 56/42% | Hip fracture (cycle 2) | Probable |
5 | None/54% | MI/known CAD | Probable |